The outcomes of clinical trail of Qiliqiangxin(QUEST trial) presented at ESC Congress 2023
The QUEST study confirmed that Qiliqiangxin group (combined with standardized treatment) reduced the risk of composite endpoint events by 22% compared with the control group (reducing the risk of rehospitalization for worsening heart failure and cardiovascular death), providing effective treatment drugs for improving the long-term prognosis of chronic heart failure.
——Presented at ESC Congress 2023
What kind of drugs that can be used to prevent heart failure are on sales in the pharmacies?
How do these western medicines work?
Standard treatment plan for chronic heart failure - "Golden Triangle" or "Four Kinds of Western Medicines"
Our heart is like a donkey and the pressure borne by the heart during blood pumping is like the cargo pulled by the donkey. The heart failure looks like a sick donkey pulling the cargo up the hill, showing the symptoms of exhaustion and asthma.
Alleviate symptoms
Diuretic: Used to reduce congestion, edema and other symptoms, which is equivalent to unloading the goods.
Cardiac glycoside: Used to enhance the blood pumping function of the heart, relieve the symptoms of shortness of breath and fatigue, which is equivalent to whipping the donkey.
It can relieve the symptoms and improve the life quality.
Improved prognosis
Beta-receptor blocker: Used to inhibit the over-excitability of the sympathetic nervous system, which is equivalent to making the donkey walk slowly.
ACEI/ARB: By inhibiting the activation of RAAS system, it can inhibit the enlargement of the heart and make the donkey's heart become stronger.
Inhibit the enlargement of the heart and reduce the rehospitalization rate and mortality.
Taking western medicine for a long time may aggravate the fatigue and suffer relapse.
Patients who only take the western medicines shall not stop taking these medicines, otherwise it will cause relapse.
Moreover taking these medicines for a long time will lead to the decreased blood pressure, slow heart rate and aggravated fatigue, which is not a permanent cure.
Qiliqiangxin - a revolutionary breakthrough in the treatment of the heart failure.
The traditional Chinese medicine believes that the pathogenesis of chronic heart failure is a systemic disease under which the body is in a state of Qi deficiency and blood stagnation for a long time, resulting in poor blood supply and dysfunction of viscera. The most important symptoms are as follows:
Three advantages of treating heart failure with Qiliqiangxin.
Advantage 1: One drug is equal to four drugs, treating the chronic heart failure fundamentally.
It is the only compound traditional Chinese medicine with four functions of strengthening heart, promoting diuretic therapy and vascular dilation and inhibiting enlargement of heart.
- Its heart strengthening effect is equivalent to the digoxin, without the side effect of digitalis of being susceptible to poisoning;
- It has a significant diuretic effect, without the side effects of diuretic resistance, electrolyte disturbance and aggravated neuroendocrine activation caused by the furosemide agents;
- It can reduce the angiotensin II level, with better effect than the ACEI western medicines, without the common adverse reactions of ACEI such as "dry cough, angioedema and hypotension";
- It can reduce the brain natriuretic peptide level, with better effect than Beta-receptor blocker, without the common adverse reactions of beta-receptor blockers such as "bradycardia, conduction block and hypotension";
lTemporary cure: It can significantly improve the early heart failure symptoms such as fatigue, lower limb edema, dyspnea, failing to lie on back during sleep at night caused by coronary heart disease and hypertension.
lPermanent cure: Inhibiting the enlargement of heart, improving the heart function comprehensively, delaying the development of heart failure and reducing the recurrence of disease.
Advantage 2: Prevention and treatment are combined to reduce the rehospitalization rate and death risk.
It has been clinically confirmed by Fuwai Hospital of Chinese Academy of Medical Sciences, The First Affiliated Hospital of Nanjing Medical University and more than 20 top first-class hospitals in China:
Advantage 3: The drug is recommended for its safety and efficacy that have been demonstrated by lots of evidences.
Led by Academician Gao Runlin, Academician Zhang Boli and Professor Huang Jun, the evidence-based medicine research participated by more than 30 national top first-class hospitals can prove that Qiliqiangxin has an obvious curative effect on treatment of chronic heart failure, without toxic side effects.
The outcomes of clinical trail of Qiliqiangxin(QUEST trial) presented at ESC Congress 2023
